Evidence map›Paper›PMID 36394699›Full record

ArticleJournal of cancer research and clinical oncology2023

Human papillomavirus is an important risk factor for esophageal carcinoma in a Chinese population.

Wenjun Yuan, Shuying Li, Jun Jia, Li Wang, Yuchao Huang, Minglian Wang, Fei Xie, Jintao Li, Yanzhe Hao

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Wenjun YuanBeijing International Science and Technology Cooperation Base of Antivirus Drug, Beijing Key Laboratory of Environmental and Viral Oncology, Faculty of Environment and Life, Beijing University of Technology, 100 Pingleyuan, Chaoyang, Beijing, 100124, People's Republic of China.
Shuying LiHebei Key Laboratory for Chronic Diseases, North China University of Science and Technology, 21Bohai Dadao, Caofeidian, Tangshan, 063000, Hebei, People's Republic of China.
Jun JiaKey Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing, VIP-II Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital & Institute, Beijing, 100142, People's Republic of China.
Li WangDepartment of Materials and Manufacturing, Beijing University of Technology, 100 Pingleyuan, Chaoyang District, Beijing, 100124, People's Republic of China.
Yuchao HuangBeijing Jinhao Pharmaceutical Co., LTD., Beijing Economic Development Zone, 7 Yuncheng Street, Beijing, People's Republic of China.
Minglian WangBeijing International Science and Technology Cooperation Base of Antivirus Drug, Beijing Key Laboratory of Environmental and Viral Oncology, Faculty of Environment and Life, Beijing University of Technology, 100 Pingleyuan, Chaoyang, Beijing, 100124, People's Republic of China.
Fei XieBeijing International Science and Technology Cooperation Base of Antivirus Drug, Beijing Key Laboratory of Environmental and Viral Oncology, Faculty of Environment and Life, Beijing University of Technology, 100 Pingleyuan, Chaoyang, Beijing, 100124, People's Republic of China.
Jintao LiBeijing International Science and Technology Cooperation Base of Antivirus Drug, Beijing Key Laboratory of Environmental and Viral Oncology, Faculty of Environment and Life, Beijing University of Technology, 100 Pingleyuan, Chaoyang, Beijing, 100124, People's Republic of China. ljt2008@bjut.edu.cn.
Yanzhe HaoNHC Key Laboratory of Medical Virology and Viral Diseases, Chinese Center for Disease Control and Prevention, National Institute for Viral Disease Control and Prevention, Beijing, 100052, China. hzhaoyanzhe@163.com.
Beijing University of Technology · CNNational Institute for Viral Disease Control and Prevention · CNNorth China University of Science and Technology · CNPeking University · CN

Funding

Scientific Research Project of the Beijing Educational Committee KM201910005004
6 · The paper itself

Abstract

purposeDifferent types of HPV have been associated with cancer in humans, but the role of HPV in esophageal cancer (EC) is controversial. The purpose of this study was to evaluate the correlation between HPV infection and EC in the Chinese population and to provide the scientific basis for the future prevention, control, early diagnosis, and treatment strategies of EC in China.

methodsPCR detected HPV infection in 1112 esophageal cancer tissue samples, and 89 HPV-positive samples were detected by genotyping. Proximity ligation assays (PLAs) and immunohistochemistry were used to detect the expression of HPV E6 and E7 proteins. Real-time fluorescent quantitative PCR was used to detect the integration of HPV16 E6. The level of HPV-specific antibody IgG in serum was detected by ELISA and PLA.

resultsThe positive rates of HPV L1, HPV16, HPV18, hpv16 + 18 E6 and hpv16/18 E6 in 1,112 EC tissue samples were 77.6%, 41.4%, 27.2%, 14.2% and 55.4% respectively. Multiple HPV subtypes were detected in HPV-positive EC samples. PLA showed that E6 and E7 were expressed in EC109 and formed complexes with p53 and pRb, respectively. Immunohistochemistry showed that the positive rates of hpv16 + 18 E6 and E7 in HPV-positive EC samples were 56.4% and 37.0%, respectively. HPV-DNA integration rate in HPV-positive EC tissues (88.79%) was higher than that in adjacent tissues (54.17%). HPV antibody was found in the serum of EC patients by a serological test.

conclusionThe study suggests that HPV, especially HPV16 and HPV18, the infection may be a risk factor for EC in the Chinese population and that the E6 protein may play a key role in HPV-associated malignancies. These results may be important for the prevention and treatment of HPV-positive EC in China.

Indexed as

Esophageal NeoplasmsOncogene Proteins, ViralPapillomavirus InfectionsEast Asian PeopleHuman papillomavirus 16Human papillomavirus 18Human Papillomavirus VirusesHumansReal-Time Polymerase Chain ReactionOncogene Proteins, ViralE6Esophageal cancerHuman papillomavirusInfectionIntegration

Identifiers

PMID36394699
PMCPMC10349784
OpenAlexW4309245574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.